Success in finding a crystalline solid form of a pharmaceutical parent compound (PC) with optimized properties using conventional screening procedures is limited by small quantities of PCs available during the early stages of drug development that constrain the screening of experimental conditions. Microfluidic platforms reduce sample volumes of PC and precipitant (salts, cocrystal formers, or antisolvents) solutions [1] thereby allowing for screening a larger number of conditions using the limited amount of PC. High throughput screening utilizing small quantities of PC could enable early identification of possible solid forms of PCs and help reduce the cost in terms of time and money invested in solid form development. To date, we have reported on a polymerbased microfluidic array-type platform to screen for solid forms of PCs that employ free interface diffusion mixing [2], antisolvent addition [3], and solvent evaporation [4].
展开▼
